← feed

Is NCT02392117 results overdue?

Yes — results are overdue. Primary completion was 2018-03-19; the FDAAA-801 reporting deadline (2019-03-19) passed 2697 days ago and no results are posted on ClinicalTrials.gov.

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus

NCT IDNCT02392117 ↗
SponsorNovo Nordisk A/S (INDUSTRY)
Public issuerNOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
Phase
StatusCOMPLETED
Primary completion2018-03-19 (ACTUAL)
Reporting deadline2019-03-19 (completion + 365d)
Days overdue2697
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 f86ace947722b141… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02392117. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →